Skip to content

Research on serum biomarkers of non-insulin resistant patients with PCOS based on proteins chip

Research on serum biomarkers of non-insulin resistant patients with PCOS based on proteins chip

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000033867
Enrollment
Unknown
Registered
2020-06-14
Start date
2017-10-01
Completion date
Unknown
Last updated
2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovary Syndrome

Interventions

Sponsors

Lanzhou University Second Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: For participants: 1. aged 20-35 years old; 2. diagnosis of PCOS according to the Rotterdam 2003 criteria (Rotterdam, 2004) which requires at least two of the following three criteria: (1) Rare ovulation and/or anovulation (less than eight menstrual cycles in one year or menstrual cycles longer than 35 days) (Azziz et al., 2004); (2) clinical and/or biochemical signs of hyper androgenism; (3) polycystic ovaries (each ovary presents 12 or more follicles measured 2-9 mm in diameter and/or ovarian volume >= 10 ml) and exclusion of other aetiologies of high androgens (e.g. Congenital adrenal hyperplasia, cushing's syndrome, androgen-secreting tumors, etc). For control group: 1. healthy women who underwent regular physical examination every year before participation; 2. aged 20-35 years old; 3. regular menstrual cycles (28-35 days).

Exclusion criteria

Exclusion criteria: Experimental group: 1. pregnant state; 2. bad habits(e.g. smoking, drinking alcohol, etc); 3. History of hormone drugs within at least previous three months, including ovulation-promoting drugs, oral contraceptives, oestrogenic, anti-androgenic drugs and other hormonal drugs. Control group: 1. clinical or biochemical signs of hyper androgenism; 2. pregnant state; 3. smoking or drinking; 4. bad habits(e.g. smoking, drinking alcohol, etc); 5. history of hormone medicine within at least previous three months the same as PCOS patients; 6. Vaginal or colorectal ultrasound suggested changes of polycystic ovaries.

Design outcomes

Primary

MeasureTime frame
Using high-throughput proteins chip technology (including 640 cytokines) to compare expression of proteins in mixed serum of parts of samples between IR and Non-IR group;

Secondary

MeasureTime frame
he clinical characteristics and laboratory indications between IR and Non-IR group;

Countries

China

Contacts

Public ContactFang Wang

Lanzhou University Second Hospital

wangfang4323@126.com+86 13919302888

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026